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Aims. Previous epidemiological investigations of the relationship between smoking and acutemountain sickness (AMS) risk yielded
inconsistent findings. Therefore, a meta-analysis of observational studies was performed to determine whether smoking is related
to the development of AMS. Methods. Searches were performed on PubMed, Scopus, Embase, and Web of Science for relevant
studies that were published before November 2016 reporting smoking prevalence and AMS. Two evaluators independently selected
studies, extracted data, and assessed study quality.The pooled relative risks (RRs) and 95% confidence intervals (CIs) were obtained
using random-effects models. Subgroup analyses were performed according to the type of participant, altitude, and study design.
Results. A total of 11 observational studies involving 7,106 participants, 2,408 of which had AMS, were eligible for inclusion in this
meta-analysis. The summary RR for AMS comparing smokers to nonsmokers was 1.02 (95% CI: 0.83 to 1.26). Specific analyses for
altitude, type of participant, and study design yielded similar results. There was significant heterogeneity for all studies (𝑄 = 37.43;
𝑃 < 0.001; 𝐼2 = 73%, 95% CI: 51% to 85%). No publication bias was observed (Egger’s test: 𝑃 = 0.548, Begg’s test: 𝑃 = 0.418).
Conclusions. The meta-analysis indicates that no difference was found in AMS risk with regard to smoking status.
1. Introduction
Climbers, trekkers, workers, and tourists who travel to high-
altitude destinations are at risk of altitude illness due to
hypoxia. Altitude illness, which includes acute mountain
sickness (AMS), high-altitude cerebral edema (HACE), and
high-altitude pulmonary edema (HAPE), may occur in any
traveller who reaches 2,500 meters above sea level (MASL)
or higher if inadequate acclimatisation occurs [1]. Millions of
people travel to typical high-altitude destinations annually,
such as Cuzco (3400 MASL, Peru), La Paz (3780 MASL,
Bolivia), Lhasa (3660 MASL, Tibet), Everest Base Camp
(5364 MASL, Nepal), and Kilimanjaro (5895 MASL, Tanza-
nia).
The most common form of altitude illness is AMS, which
generally resolves within 24–72 hours of acclimatisation.The
incidence of AMS varies from 25% to 75% [1] in the general
population but is unknown in smokers. AMS risk is affected
by a traveller’s characteristics such as genetic traits [2], age [3],
previous exposures to high altitude and experience [4], des-
tinations, itinerary, rate of ascent, and exertion [5]. Alcohol
intake avoidance [4], carbohydrate ingestion [6], water intake
[7], and acetazolamide use [8] may prevent AMS. Training or
physical fitnessmay not be significantly associatedwithAMS,
but the influence of some covariates, such as obesity or smok-
ing status, is debatable. High altitudes cause a decrease in
barometric pressure and inspired oxygen pressure.Therefore,
reduced alveolar oxygen pressure, oxygen arterial pressure,
and oxygen arterial saturation rate occur, which greatly
reduces oxygen availability into tissues.
Smoking tobacco increases the carbon monoxide (CO)
concentrations in the airways and the blood. Carbonmonox-
ide’s haemoglobin-binding affinity is over 200 times that of
oxygen. The level of CO is an indirect measure of blood
carboxyhaemoglobin (COHb). The percentage of COHb is
the proportion of red blood cells carrying CO instead of
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oxygen.The normal level of CO for a nonsmoker depends on
background levels in the air but is usually lower than 5 ppm,
and percent of COHb is lower than 1.43 [9]. The level of CO
for a smoker is usually much higher according to the time of
the day, the number of tobacco products smoked, and how
the smoke is inhaled. The level of CO for a smoker of 20
cigarettes per day is usually around 20 ppm and percent of
COHb higher than 3.83. Increased levels of carbonmonoxide
in the bloodstream have a negative ionotropic effect [10] and
can limit the amount of oxygen transported in muscular
capillaries, which adversely affects skeletal muscle perfor-
mance. Smoking causes an increase in carboxyhaemoglobin
levels, resulting in a leftward shift of the oxyhaemoglobin
dissociation curve when carbon monoxide is present in
the blood. Carbon monoxide reduces the formation of 2,3-
DPG by inhibiting glycolysis in the erythrocyte. Nicotine
stimulates the sympathetic nervous system, which can lead
to increased levels of catecholamine, thereby increasing a
person’s heart rate and stroke volume [11]. The tar produced
by the burning of tobacco can increase pulmonary airway
resistance or reduce the contact surface area between oxygen
and pulmonary capillaries, thereby decreasing the capacity of
the arteries to transport oxygenated blood during exercise.
Therefore, smokers exhibit a lower capacity to transport
oxygen because of increased carboxyhaemoglobin and diffi-
culties in breathing control and alterations in vascular tone,
neurotransmission, and cellular metabolism due to carbon
monoxide and lower vasodilatation in hypoxic environments
than nonsmokers [11].
Previous epidemiological investigations of the relation-
ship between smoking and acute mountain sickness (AMS)
risk yielded inconsistent findings. Some studies identified
smoking as a risk factor [12, 13] or a protective factor [11, 14],
but other studies failed to show any significant association [4,
15–18]. However, only one study was specifically designed to
study smoking as a risk factor forAMS [11].Therefore, ameta-
analysis of observational studies (cross-sectional studies,
case-control or cohort studies) was performed to determine
whether smoking was related to the development of AMS.
2. Materials and Methods
2.1. Data Sources and Search Strategy. ThePRISMAstatement
[19] for the reporting of systematic reviews recommended
by the Cochrane Collaboration was followed while conduct-
ing this meta-analysis (see Figure 1). Observational studies
(cross-sectional studies, case-control, and cohort studies) on
smoking and the risk of AMS were included in our meta-
analysis, and language, publication status, or article type was
not considered. Two investigators conducted a systematic
literature search of the electronic databases PubMed (from
1965 to November 2016), SCOPUS (from 1965 to November
2014), Embase (from 1965 to November 2016), and Web
of Science (from 1986 to November 2016). Searches were
performed using the search terms under two search themes
that were combined using the Boolean operator “AND.”
For the theme of “AMS,” a combination of Medical Sub-
ject Headings (MeSHs), entry terms, and text words was
used: “acutemountain sickness,” “altitude illness,” “mountain
sickness,” “high-altitude cerebral edema,” and “HACE.” For
the theme of “Smoking,” “smoking” and “tobacco” were used.
In addition, all references cited in relevant original and review
articles were searched manually.
2.2. Selection Criteria. Eligible studies met the following
inclusion criteria: (1) the study was an observational study
(cross-sectional study, case-control study, nested case-control
study, or cohort study); (2) the exposure of smoking was
described; (3) the outcome of interest was AMS; (4) the
study reported the percentage of AMS according to tobacco
exposure, the relative risk (RR) or odds ratio (OR), and the
95% confidence interval (CI) for the association between
smoking and risk of AMS; and (5) a Newcastle-Ottawa Scale
(NOS) or adapted Newcastle-Ottawa Scale (aNOS) score of
5 or greater indicated moderate- to high-quality studies [20].
Studies that did not document the frequency of AMS, animal
experimentation studies, and mechanistic research studies
were excluded. Studies in which the exposure of interest
was not sufficiently explained were also excluded to avoid
the combination of studies that were not comparable. Two
investigators independently conducted the study selection.
2.3. Data Extraction and Quality Assessment. Two reviewers
independently performed data extraction and quality assess-
ment. The following information was extracted from each
eligible study: first author’s surname, year of publication,
study location, study design, source of study population, type
of exposure or population, sample size, number of events,
proportion of smokers, definition of smoking, definition of
AMS, estimated effect size (ORorRR), 95%CI, and covariates
adjusted in statistical analyses. No studies reported several
multivariable-adjusted effect estimates based on smoking
behaviour. Therefore, a result that was fully adjusted for
potential confounding variables was not selected. Quality
assessment was conducted using the nine-star Newcastle-
Ottawa Scale (NOS); see Table 1. We considered studies with
an NOS score of 5 or greater to be moderate- to high-
quality studies [20]. After data extraction and assessment, the
informationwas examined and adjudicated independently by
an investigator who referred to the original articles.
2.4. Statistical Analysis. The relationship between smoking
and risk of AMS was examined using the OR or RR and 95%
CI in each study or the frequency of AMS in smokers versus
nonsmokers. Prevalence ratios (PRs) in the cross-sectional
studies and the OR in case-control studies approximated the
RR because the absolute risk of AMS is low [21]. The AMS
detected was the incidence of AMS in all cross-sectional
studies because these studies asked about the appearance
of AMS when the subjects reached the altitude where the
study was conducted. The incidence of AMS and its 95%
CI was described depending on smoking status and altitude.
Therefore, the PRs and ORs should likely be considered
RRs in these studies. A meta-analysis comparing the risk
of AMS between smokers and nonsmokers in all included
studies was performed. Smokers were defined as subjects who
smoked 10 ormore cigarettes per day currently.Mountaineers
were defined as trekkers or climbers who were physically fit
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Figure 1: PRISMA flow chart of the included studies selection process.
Table 1: Characteristics of included studies according to Newcastle-
Ottawa Quality Assessment Scale.
Study Selection Comparability Exposure/outcome
NOS
scale
Wu et al., 2012 ⋆ ⋆ ⋆ ⋆ ⋆⋆ 6
Li et al., 2011 ⋆ ⋆ ⋆ ⋆⋆ ⋆⋆ 7
Wagner et al., 2008 ⋆ ⋆ ⋆ ⋆ ⋆ 5
You et al., 2012 ⋆ ⋆ ⋆ ⋆⋆ ⋆⋆ 7
Vinnikov et al., 2014 ⋆ ⋆ ⋆ ⋆ ⋆⋆ 6
McDevitt et al., 2014 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Mairer et al., 2009 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Mairer et al., 2010 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Mairer et al., 2010 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Schneider et al., 2001 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Schneider et al., 2001 ⋆ ⋆ ⋆ ⋆ ⋆ 5
Note. Each star represents a high-quality criterion accomplished by the study.
persons, who knew the rules of high-altitude climbing, and
were aware of the importance of acclimatisation. AMS was
defined as an Environmental Symptom Questionnaire (ESQ)
score greater than 0.7 [22]; Lake Louise score (LLS) greater
than or equal to 3 [23]; or using a Study-Specific Question-
naire (SSQ) [12, 15, 24]. If a single study reported results for
different populations (e.g., different altitudes or destinations)
but did not report the overall results, the results for each
population were calculated as a separate study [25]. The ESQ
has 67 questions, evaluates the presence and severity of AMS
symptoms (headache, nausea, and the general feeling of ill
health), and determines whether an individual has no AMS
(ESQ < 0.7) or AMS (ESQ ≥ 0.7). The ESQ contains many
superfluous questions, requires multiplying each response
by a factorial weight, and has been criticised because it is
validated against the simple item, “I feel sick.” The LLS has
five questions, evaluates the presence and severity of AMS
symptoms (headache, gastrointestinal symptoms, fatigue and
weakness, dizziness and light-headedness, and difficulty
sleeping), and determines whether an individual has no AMS
(LLS < 3), mild AMS (LLS 3–5), or severe AMS (LLS >
5). The LLS has been validated against clinical assessment.
Some studies show that for criterion scores yielding similar
prevalence of AMS, ESQ labels 20% of cases differently when
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compared to LLS. The SSQ means that each study used a
specific questionnaire as a translation of a Chinese scoring
system for AMS [15, 24], which presents a high correlation
to LLS (𝑟 = 0.820) or restricted the case definition of AMS
to those persons who were deemed ill enough to undergo
compression chamber treatment [12]. Reported incidences
and identifiable predictive factors of AMS [26] depend on
study design (RCTs in comparison to cohort and cross-
sectional studies). Subsequently, we conducted subanalyses
by epidemiological study design (cross-sectional studies and
case-control studies versus cohort studies), altitude (high
altitude defined as <3500 MASL versus very high altitude
defined as ≥3500 MASL) [11], type of participant character-
istics (mountaineers versus nonmountaineers), and NOS (≥6
versus <6) as a sensitivity analysis. According to inclusion
criteria, NOS < 6 refers to NOS = 5. All included studies
presented different quality assessment scores. Therefore, we
performed sensitivity analyses according to NOS score and
designated NOS scores from 5 to 6 as moderate and NOS
scores equal to or greater than 7 as high. A random-effects
model was used to estimate the pooled RRs with 95% CIs
because there was evidence of heterogeneity [27]. Forest plots
were used to assess the RR estimates and corresponding 95%
CIs visually. We could not perform a two-stage, random
effect, dose–response meta-analysis to examine the potential
nonlinear relationship between smoking dose and risk of
AMS because smoking dose was not reported in most
studies. Heterogeneity between studies was evaluated using
the Cochran’s 𝑄 and 𝐼2 statistics [28, 29]. The probability of
publication bias was assessed using the Egger regression test
[30] and Begg’s funnel plot [31]. We evaluated the effect of
publication bias using the trim and fill method [32]. Stata
version 12.0 software (StataCorporation, College Station, TX)
was used for all analyses, and all statistical tests were two-
sided. 𝑃 < 0.05 was considered statistically significant.
3. Results
3.1. Description of the Selected Studies. Forty-nine records
were retrieved using the specified search strategy in Novem-
ber 2016. After reading the titles and abstracts, 4 records were
excluded, and 45 studies were retained for further evaluation
by a reading of the full text. Thirty-four studies did not meet
the inclusion criteria or were not an original study. Finally,
we identified 11 full-text studies on smoking and AMS for
inclusion in the meta-analysis, including 7 cross-sectional
studies [4, 13, 16–18], 3 cohort studies [11, 14, 15], and 1
case-control study [12]. Figure 1 depicts the search process.
These 11 studies included 7,106 participants and 2,408 AMS
cases (5 studies in Asia; 5 studies in Europe; and 1 study in
America). Table 2 presents the general characteristics of the
included studies. Studies asked the same fundamental ques-
tion about risk factors linked to AMS, but the populations
(mountaineers, tourists, workers, and military troops), study
design (cross-sectional studies, nested case-control study in
an occupational cohort, and cohort studies), AMS definition,
and smoking status definition were not identical. Therefore,
the studies varied in specific ways.
3.2. Description of the AMS Incidence. The overall incidence
of AMS in the studied population was 25.02% (95% CI, 24.01
to 26.03); when they climbed to altitudes between 2500MASL
and 3500MASL, it was 19.61% (95%CI, 16.16 to 23.06); higher
than 3500 MASL, it was 25.44% (95% CI, 24.39 to 26.49); if
they were climbers or mountaineers, it was 34.31% (95% CI,
32.50 to 36.12); and, in nonmountaineers, it was 19.54% (95%
CI, 18.38 to 20.70).
3.3. Smoking and Risk of AMS. Figure 2 shows the summary
RR of AMS for smoking status. The summary RR for
smokers was 1.02 (95% CI, 0.83 to 1.26) for AMS, with some
heterogeneity (𝐼2 = 73.0%, 𝑃 < 0.001).The Begg’s funnel plot
did not show any asymmetry (𝑃 = 0.418), and Egger’s test
revealed no publication bias (𝑃 = 0.548).
3.4. Subgroup Analysis. Table 3 shows the results of subgroup
analyses according to study design, altitude, quality assess-
ment of the studies, and type of participant. The reported RR
always was considered smoking over nonsmoking. Restric-
tion of analysis to cohort studies revealed a summary RR of
AMS for smoking status of 0.79 (95% CI, 0.54 to 1.17) with
high heterogeneity (𝐼2 = 89.0%, 𝑃 < 0.001). Two cohort
studies showed a statistically protective effect of smoking on
AMS development. The RR for AMS risk for case-control
or cross-sectional studies was 1.20 (95% CI, 0.99 to 1.47)
without heterogeneity (𝐼2 = 32.0%, 𝑃 = 0.169). Two of these
studies showed a significant risk effect of smoking on AMS
development. Stratification by altitude revealed an RR for
AMS of 1.24 (95%CI, 0.78 to 1.95) without heterogeneity (𝐼2 =
25.0%, 𝑃 = 0.922) for altitudes below 3500 MASL and an RR
of 1.00 (95% CI, 0.79 to 1.26) with some heterogeneity (𝐼2 =
78.0%, 𝑃 < 0.001) for altitudes equal to or above 3500MASL.
However, controversial association results were present. The
RR for AMS according to type of exposure or population was
1.17 (95% CI, 0.97 to 1.41) without heterogeneity (𝐼2 = 23.0%,
𝑃 = 0.253) for mountaineers or in studies with moderate
quality (NOS = 5 or aNOS = 5) and 0.92 (95% CI, 0.62 to
1.36) with high heterogeneity (𝐼2 = 87.0%, 𝑃 < 0.001) for
nonmountaineers (travellers, workers, or military troops) or
in studies of high quality (NOS ≥ 6 or aNOS ≥ 6).
3.5. Sensitivity Analysis. Table 4 shows the results of sensitiv-
ity analyses. The sensitivity analysis removed one study at a
time to assess the robustness of the overall results. Sensitivity
analyses and subgroup analyses results were consistent with
the overall results, which indicated that there was no hetero-
geneity from study design, study quality, altitude, or type of
participants. However, one study [14] decreased statistically
significant the heterogeneity to 59%, probably because it is a
military cohort study conducted in China at an altitude over
4300 MASL, and the AMS definition was LLS ≥ 4.
4. Discussion
The meta-analysis indicates that no difference was found in
AMS risk with regard to smoking status (RR 1.02, 95% CI,
BioMed Research International 5
Table 2: Characteristics of included studies.
Study Final altitude (MASL) Design 𝑛 Smoking AMS Smokingadjustment
Wu et al., 2012
4552MASL (4292–4905MASL),
Qinghai-Tibet railroad; occupational
cohort
Cohort study 382
Smoking status:
(i) No smoker
(ii) Smoker < 20 cig/d
(iii) Smoker 20 cig/d
(iv) Smoker > 20 cig/d
LLS ≥ 4 Absent
Li et al., 2011 (2900–4300MASL); Qinghai Tibetplateau; military cohort Cohort study 3727
Smoking status:
(i) No current smoker
(ii) Current smoker
SSQ Present
Wagner et al., 2008 4419MASL (2550–4419) Mt. Whitney,California, USA; Hikers Cross-sectional 886
Smoking status:
(i) Smoker
(ii) Nonsmoker
LLS ≥ 3 Absent
You et al., 2012 4300MASL (2860–5250MASL); Militarycohort Cohort study 314
Smoking status:
(i) Not current
smoker
(ii) Current smoker
LLS ≥ 4 Present
Vinnikov et al., 2014
4000MASL (3800–4200MASL) Tyan
Shan Mountains, Kyrgyzstan;
Occupational cohort
Nested
case-control
(1 : 2)
45
Smoking status:
(i) Smoker <10 cig/d
(ii) Smoker ≥10 cig/d
(iii) Nonsmoker
SSQ Absent
McDevitt et al., 2014 (3500–5400MASL); Thorong-La,Annapurna, Nepal; Trekkers Cross-sectional 332
Smoking status:
(i) Smoker
(ii) Nonsmoker
LLS ≥ 3
LLS ≥ 5
ESQ > 0.7
Present
Mairer et al., 2009 2200–3500MASL Eastern Alps;Mountaineers Cross-sectional 431
Smoking status:
(i) Smoker
(ii) Nonsmoker
LLS ≥ 4 Absent
Mairer et al., 2010 3454-4049MASL in Eastern Alps;Mountaineers Cross-sectional 79
Smoking status:
(i) Smoker
(ii) Nonsmoker
LLS ≥ 4 Absent
Mairer et al., 2010 3817-4808MASL in Western Alps;Mountaineers Cross-sectional 83
Smoking status:
(i) Smoker
(ii) Nonsmoker
LLS ≥ 4 Absent
Schneider et al., 2001 4559MASL; Capanna Margherita, Italy;Mountaineers in 1996 and 1999 Cross-sectional 440
Smoking status:
(i) No smoking
(ii) Smoking
ESQ > 0.7 Present
Schneider et al., 2001 4559MASL; Capanna Margherita, Italy;Mountaineers in 2000 Cross-sectional 387
Smoking status:
(i) No smoking
(ii) Smoking
ESQ > 0.7 Present
SSQ: study-specific questionnaire; AMS: acute mountain sickness; ESQ: environmental symptom questionnaire; NS: not stated; LLS: Lake Louise Score.
0.83 to 1.26) independent of altitude, training, or type of
questionnaire used.
4.1. Smoking. Smoking status is thought to participate in
acute mountain sickness, and it is considered a traditional
risk factor for the development of AMS [1, 11]. However, some
epidemiological studies that evaluated the development of
AMS did not describe smoking as a risk factor, and most
epidemiological studies were not specifically designed to
evaluate the relationship between smoking and AMS. These
studies describe controversial results because negative and
positive associations are reported. This lack of agreement
between the results of previous studies may be due to
differences in altitude, study population, epidemiological
designs, or residual confounding. Previous studies were
systemically reviewed to explore the association between
smoking and the risk of AMS because of the importance
of this possible association in clinical practice and public
health. To our knowledge, prior to our study, two meta-
analyses explored the association between smoking and AMS
[33, 34] with different results. Vinnikov et al., 2016, found
that smoking was not significantly associated with AMS (OR
0.88, 95% CI, 0.74 to 1.05) whereas Xu et al. [34] found
that smoking may protect against AMS development (OR
0.71, 95% CI, 0.52 to 0.96). Different selection criteria may
lead to different results; we used strict inclusion criteria,
high-quality studies, and control for confounding variables
and heterogeneity by different methodological tools. Our
meta-analysis results contrast with one meta-analysis [34]
but accord with the other one [33]. Meta-analysis of 11
observational studies suggested an AMS incidence rate of
25.02%, being lower if the traveller climbed below 3500MASL
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Table 3: Subgroup analyses of RRs for the association between AMS and smoking.
Group Number of studies Pooled RR (95% CI) Heterogeneity
𝐼
2
𝑃
Overall 11 1.02 (0.83, 1.26) 73.0% <0.001
Study design
Cross-sectional studies and case-control study 8 1.20 (0.99, 1.47) 32.0% 0.169
Cohort studies 3 0.79 (0.54, 1.17) 89.0% <0.001
Altitude
<3500 MASL 2 1.24 (0.78, 1.95) 25.0% 0.922
≥3500 MASL 9 1.00 (0.79, 1.26) 78.0% <0.001
Quality assessment
NOS/aNOS = 5 7 1.17 (0.97, 1.41) 23.0% 0.253
NOS/aNOS = 6-7 4 0.92 (0.62, 1.36) 87.0% <0.001
Type of participant
Mountaineer 7 1.17 (0.97, 1.41) 23.0% 0.253
Nonmountaineer 4 0.92 (0.62, 1.36) 87.0% <0.001
AMS: acute mountain sickness; CI: confidence interval; MASL: meters above sea level; NOS: Newcastle-Ottawa Quality Assessment Scale; aNOS: adapted
Newcastle-Ottawa Quality Assessment Scale; RR: relative risks. Relative risks were obtained using the DerSimonian and Laird random-effect model.
ID
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
71
746
25
36
9
25
12
4
3
21
15
182
2242
51
138
17
37
61
9
13
72
56
102
450
352
83
6
133
58
26
26
99
106
200
1485
835
176
28
295
370
70
70
368
331
422812032878575
Total (95% CI)
Total events
16.4%
43.0%
6.8%
12.3%
0.8%
5.0%
2.8%
1.0%
1.4%
5.5%
5.2%
100.0%
0.1 1 10
0.76 (0.61, 0.96)
1.11 (0.95, 1.29)
1.16 (0.87, 1.56)
0.55 (0.40, 0.76)
2.47 (1.07, 5.72)
1.50 (1.16, 1.94)
1.25 (0.72, 2.20)
1.20 (0.54, 2.64)
0.62 (0.22, 1.75)
1.08 (0.73, 1.61)
0.84 (0.53, 1.33)
1.02 (0.83, 1.26)
McDevitt
Wu et al., 2012
Li et al., 2011
You et al., 2012
Mairer et al., 2009
Mairer et al., 2010 (Western Alps)
Mairer et al., 2010 (Eastern Alps)
Schneider et al., 2002 (Substudy 1)
Schneider et al., 2002 (Substudy 2)
Vinnikov et al., 2014
Wagner et al., 2008
Author
Smokers
TotalEvents Weight (%) RR (95% CI)
Nonsmokers
TotalEvents
Heterogeneity: Cochran’s Q = 37.43 (P < 0.001); I2 = 73%
Test for overall eect: Z = 0.22 (P = 0.828)
Figure 2: Forests plots of relative risks of AMS and smoking. AMS: acute mountain sickness; CI: confidence interval; RR: relative risks. The
relative risks were obtained by random effect (DerSimonian and Laird).
than if the traveller climbed higher than 3500 MASL. This
probably reflects comparison between climbers, who go to
higher altitudes, and nonclimbers. Meta-analysis suggested
that smoking was not significantly associated with AMS risk.
The association was not significantly affected by study design,
type of exposure or participants, altitude, study quality, or
severity of AMS. However, we could not use the adjusted OR
for the meta-analysis because most authors did not adjust
for smoking in the original manuscripts. Therefore, these
data were not available. However, evaluation of cigarettes
per day might lend support for an association between
exposure and disease [25]. Therefore, further investigation
into the role of smoking in AMS risk is needed, with an
emphasis on smoking duration and the number of cigarettes
BioMed Research International 7
Table 4: Results of sensitivity analyses for AMS risk by smoking
status.
ID Study omitted Pooled RR (95%CI)
Heterogeneity
𝐼
2
𝑃
(1) Wu et al., 2012 1.07 (0.85, 1.34) 70.0% <0.001
(2) Li et al., 2011 1.02 (0.78, 1.32) 76.0% <0.001
(3) Wagner et al., 2008 1.01 (0.80, 1.27) 73.0% <0.001
(4) You et al., 2012 1.10 (0.92, 1.32) 59.0% 0.002
(5) Vinnikov et al.,2014 0.98 (0.80, 1.21) 73.0% <0.001
(6) McDevitt et al.,2014 0.97 (0.78, 1.19) 67.0% <0.001
(7) Mairer et al., 2009 1.01 (0.81, 1.26) 76.0% <0.001
(8) Mairer et al., 2010(Eastern Alps) 1.02 (0.82, 1.27) 76.0% <0.001
(9) Mairer et al., 2010(Western Alps) 1.04 (0.84, 1.29) 75.0% <0.001
(10) Schneider et al.,2001 (sub-study 1) 1.02 (0.81, 1.28) 76.0% <0.001
(11) Schneider et al.,2001 (sub-study 2) 1.04 (0.83, 1.31) 75.0% <0.001
AMS: acute mountain sickness; CI: confidence interval; RR: relative risks.
Relative risks were obtained using theDerSimonian and Laird random-effect
model.
smoked. Heterogeneity is often a concern in a meta-analysis.
Evidence of substantial heterogeneity across studies of the
associations of smoking and AMS risk was observed in our
meta-analysis, primarily in high-quality cohort studies, high
altitudes, and mountaineer populations. Smoking and AMS
definitions without sample size estimations differed in across
studies, which affected prospective studies because the power
to confirm the hypothesis was suboptimal. Moreover, the
included studies were conducted in different countries and
on different continents, and these populations likely have
different smoking prevalence, lifestyle, prevention measures,
and AMS incidence.Therefore, the characteristics of subjects
and study design might have contributed to the observed
heterogeneity. The subgroup analyses of cross-sectional or
case-control studies, low altitudes, moderate quality obser-
vational studies, and mountaineers detected no significant
heterogeneity (𝑃 > 0.05). These other studies likely did not
estimate a formal sample size, but the feasibility to develop
these study designs in a short period was demonstrated. The
same authors developed some of them, and heterogeneity was
almost absent.
4.2. Altitude. We ignored the specific ascent rate in each
study; hence, we considered only the maximum altitude the
participants reached. Low altitude was defined when the
highest altitude reached was below 3500 MASL; moderate to
high altitude occurred when the greatest altitude was equal
to or higher than 3500 MASL. No significant reduction in
AMS riskwas associatedwith low or high altitude in smokers.
Some authors found that smoking protected against AMS
development [11, 14], whereas others found that smoking
increased AMS development [12, 13] in different altitudes.
4.3. Mountaineers. The effect of the type of participants was
based on the likely presence and absence of training inmoun-
taineers and nonmountaineers, respectively. Most evaluated
studies did not provide stratified data of AMS by smoking
status or previous physical training (e.g., the number of
nights spent above 3000MASL or months before the ascent).
Previous physical training could produce some impact on
acclimatisation. Therefore, the decrease in AMS incidence
could be quite similar to the smoking effect on acclima-
tisation. However, this effect was not demonstrated in the
subgroup analyses because mountaineers frequently ascend
to higher altitudes, and this group showed previous training
and a low smoking prevalence. Mountaineers showed a low
smoking prevalence (11.3%) in our subgroup analysis, and
nonmountaineers exhibited a higher prevalence (55.5%) (𝑃 <
0.001). These findings could be due to a comparison between
mountaineers, who go to higher altitudes, and nonmoun-
taineers.
4.4. Limitations. First, the observed association may be
masked by the lack of temporality because our analysis was
primarily based on cross-sectional studies. These studies
were developed in huts just prior to ascent. Therefore, the
development of AMS that was described by the authors as
prevalent episodes should likely be described as incident
events. Smoking status was described at the time of AMS
development, but smoking was obviously present before the
ascent. Moreover, unmeasured or residual confounding is
always a major concern in observational studies. The results
of sensitivity and subgroup analyses showed robustness,
and the relationship between AMS and smoking was not
influenced by study design or quality, altitude or the type
of participant or exposure. Therefore, the likelihood that
our findings resulted from other unmeasured confounders
cannot be excluded, and our meta-analysis suffers from
heterogeneity and lack of studies that specifically looked at
smoking and AMS, so more studies are needed. Second,
we were unable to evaluate the dose–response effect of
smoking on AMS development because it was not described
in any study. Third, the AMS case definition was based on
different diagnosis criteria or questionnaires. Headache is a
cornerstone symptom for the diagnosis of AMS in Western
countries; however, in China, it is not essential, and some
language discrepancies between LLS and the Chinese Scoring
System make difficult their direct comparison. Finally, one
study defined AMS according to compression chamber use,
so this study probably underestimated the mild AMS preva-
lence. Therefore, a misclassification of subjects was possible,
and the relationship between smoking and AMS risk may be
under- or overestimated. Finally, publication bias may be a
problem because studies with null effects are less likely to
be published than studies that provide statistically significant
results. Egger’s test and Begg’s funnel plots detected no
evidence of publication bias in the meta-analysis, but that
estimation may not be sufficiently accurate because the
number of included studies and population was relatively
small.
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5. Conclusions
In summary, the present meta-analysis of 11 observational
studies indicated that smoking did not either reduce or
increase the risk of AMS. However, many questions must
be addressed. Further large-scale prospective studies, using a
strict case definition of AMS and smokers and confounders,
are warranted to validate our findings.
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